The Administration Core includes Consortium Administration and Senior Leadership. Consortium Administration provides high quality, efficient and effective support to cancer center leaders, programs and members. Administration plays a major role in enabling the Consortium's scientific leaders to define the center's vision and strategic goals, implement initiatives, monitor progress in achieving objectives and secure needed resources to develop the requisite infrastructure to carry out the center's mission. Senior Leaders work together to establish a vision and implement strategies of high importance to the cancer center's development. In addition to the Center Director, Dr. Corey, senior leadership includes: two Deputy Directors, including one who oversees Clinical Research; three scientific Associate Directors (AD) for Basic Sciences, Population Sciences, and Childhood Cancers; four ADs for special areas that are high strategic priorities of the center (Solid Tumor Translational Research, Global Oncology, Minority Health and Health Disparities, Inter-Institutional Initiatives), and an AD for Administration. Together, Administration and Senior Leaders provide the necessary leadership and structure to ensure that the center is well positioned to achieve its overarching goals to improve diagnosis, treatment and prevention of cancer.
The Specific Aims of this core are to provide: 1. Efficient and cost-effective administrative coordination for the cancer center including support for CCSG grant administration, budget management, communication and coordination across the partners, and other administrative functions to support and optimize the Consortium's research productivity. 2. Efficient oversight and management of CCSG Shared Resources to assure provision of services of the highest quality. 3. Expert leadership for clinical, basic and population-based cancer research; and other areas that are high strategic priorities of the center. 4. Executive leadership and oversight of planning and execution of the cancer center vision; fostering interdisciplinary translational and inter-institutional research of the center; engaging members in the center; fostering team science and career development; and addressing the health needs of the catchment area through research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-44
Application #
9617702
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Buckley, Sarah A; Percival, Mary-Elizabeth; Othus, Megan et al. (2018) A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma :1-7

Showing the most recent 10 out of 1267 publications